- Ribometrix to receive $25M up front, ~$1B+ as milestones along with royalties on sales of therapies emerges from the collaboration
- The companies collaborated on the discovery & preclinical development of programs. Genentech will lead further development and commercialization and will have exclusive rights to several predefined targets including an exclusive global license for the development and commercialization of molecules
- Ribometrix will leverage its discovery platform to identify & optimize small molecule compounds modulating RNA function by targeting 3D RNA structures
Click here to read full press release/ article | Ref: Businesswire | Image: New Indian Express
The post Genentech Signs ~$1B Pact with Ribometrix to Develop RNA-Targeted Small Molecule Therapies first appeared on PharmaShots.